PuSH - Publikationsserver des Helmholtz Zentrums München: Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Sebelin, K.* ; Schulzki, A.* ; Kloetzel, P.M.* ; Dörken, B.* ; Pezzutto, A.* ; Subklewe, M.*

Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients.

Transplantation 82, 779-787 (2006)

PMC

Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

BACKGROUND: Immunosuppressive drugs used after organ transplantation are known to impair lymphocyte function, resulting in an increased incidence of viral associated malignancies. In vitro data indicate that immunosuppressive drugs also target dendritic cells (DCs). Our study aimed to investigate the phenotype and function of circulating myeloid DCs (mDCs) from renal/pancreas transplant recipients receiving immunosuppressive drugs. In addition, we analyzed the potential of patient monocytes to differentiate into mature DCs (MoDCs) in vitro. METHODS: Phenotype of mDCs was analyzed by fluorescence-activated cell sorter (FACS) analysis. The ability of mDCs to undergo activation was determined using cytokine bead array and FACS analysis. Allostimulatory capacity was determined by mixed leukocyte reaction. MoDCs were generated using a defined cytokine cocktail and analyzed for maturity of phenotype and function. The ability of patient-MoDCs to expand antigen-specific T cells was analyzed by tetramer staining and interferon (IFN)-gamma ELISPOT assay. RESULTS: We observed a reduced expression of CD54 (P=0.001), CD86 (P=0.032), HLA-DR (P=0.013), and CD38 (P=0.006) on patient mDCs. Upon stimulation, the expression of HLA-ABC, HLA-DR and CD86 was upregulated on patient mDCs to the same level as on control mDCs. MoDCs were equivalent to control-MoDCs regarding phenotype and function. Co-culture of peptide-pulsed patient-MoDCs with T cells resulted in significant expansion of autologous Epstein-Barr virus-specific, IFN-gamma secreting T cells. CONCLUSIONS: Our data support the notion that immunosuppressive drugs target DCs and induce a maturation defect in circulating mDCs. However, ex vivo stimulated mDCs as well as MoDCs do not show a significant impairment, suggesting that MoDCs from immunosuppressed patients can be used for immunotherapeutic strategies.

Impact Factor

Scopus SNIP

Altmetric

0.000